Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS), is a condition involving hormonal, reproductive, and metabolic health. Women with PMOS may experience irregular menstrual cycles, ovulatory dysfunction, increased androgen levels, and metabolic changes such as insulin resistance.
PMOS does not present in the same way in every woman. Its effects can extend beyond ovarian function and involve reproductive, metabolic, cardiovascular, dermatological, and psychological health. Assessment and management should therefore be tailored to the individual's clinical features, lifestyle, and healthcare needs.
What Is PMOS?
PMOS is a complex endocrine and metabolic condition that can affect several aspects of women's health. The recent international consensus process introduced Polyendocrine Metabolic Ovarian Syndrome as the new name for what was previously known as Polycystic Ovary Syndrome.
The change in terminology reflects the broader metabolic and endocrine features associated with the condition rather than focusing solely on the ovaries.
Clinical Presentation
The clinical presentation of PMOS varies considerably. Menstrual irregularity and ovulatory dysfunction may occur alongside hyperandrogenism and metabolic abnormalities, including insulin resistance.
For this reason, evaluation of PMOS involves consideration of reproductive, metabolic, and other relevant clinical features rather than a single manifestation of the condition.
PMOS and Metabolic Health
Metabolic changes are an important component of PMOS. Insulin resistance is commonly observed in women with the condition and may occur alongside hormonal and reproductive disturbances. This relationship has generated interest in nutritional approaches that may support metabolic health.
Inositol has been studied in this context because of its involvement in insulin-related cellular pathways and its potential effects on metabolic and reproductive measures. Findings vary across studies and outcomes. Inositol may therefore be considered as a nutritional option within a broader approach to PMOS management rather than as a substitute for medical treatment.
Inositol in PMOS: Myo-Inositol and D-Chiro Inositol
Myo-Inositol (MI) and D-Chiro Inositol (DCI) are the two forms of inositol most frequently studied in relation to PMOS. Both are involved in cellular signalling, including pathways associated with insulin action. Myo-Inositol has also been investigated in relation to reproductive and ovarian function.
Clinical studies have evaluated MI and DCI individually as well as in combination. Some have reported improvements in selected metabolic or reproductive measures, although results have varied across outcomes. The systematic review informing the international evidence-based guideline similarly found that the evidence for inositol differs according to the outcome assessed.
These findings have led to continued interest in inositol as a nutritional intervention for women with PMOS. However, the available evidence should be interpreted in the context of the quality and consistency of individual studies and the specific clinical outcome being considered.
What Do We Know About the 40:1 Inositol Ratio?
Several MI-to-DCI ratios have been investigated in clinical research, including a 40:1 ratio. Interest in combining the two forms relates to their distinct but interconnected roles in cellular signalling and insulin-related pathways.
The fact that a particular ratio has been studied does not mean that it has been established as the preferred ratio. Current evidence does not demonstrate that one particular ratio, dose, or combination of inositol is universally superior. The international guideline therefore does not recommend a specific inositol formulation or dosage at this time.
Key Takeaway: The 40:1 ratio should consequently be understood as a formulation that has been investigated in clinical research, rather than as a universally established therapeutic standard.
PMOSIA DS: Myo-Inositol and D-Chiro Inositol with Selected Nutrients
PMOSIA DS provides:
- Myo-Inositol: 1100 mg
- D-Chiro Inositol: 27.6 mg (approximately a 40:1 ratio)
- L-Methylfolate Calcium: 200 mcg
- Chromium Picolinate: 100 mcg
- Vitamin D3: 600 IU
PMOSIA DS combines the two forms of inositol studied in PMOS with selected micronutrients. It is intended as a nutritional component that can complement a broader approach to PMOS management. As with other nutritional interventions, its use should be considered in the context of individual requirements and appropriate clinical assessment.
The formulation is designed to provide nutritional support within an individualized approach to metabolic and reproductive health in women with PMOS.
PMOS Management: Why Individualized Assessment Matters
PMOS does not have a single universal treatment approach. Management depends on the individual's reproductive, hormonal, metabolic, and other clinical needs. Lifestyle measures, appropriate medical interventions, and nutritional approaches may form different components of an individualized management plan.
Persistent menstrual irregularity, concerns regarding ovulation or fertility, symptoms associated with androgen excess, and metabolic concerns warrant appropriate clinical assessment. A healthcare professional can evaluate the individual's symptoms, medical history, and relevant clinical findings to determine whether further investigation or treatment is required.
PMOS can present differently from one woman to another. Diagnosis and management should therefore be guided by the individual's clinical presentation and appropriate investigations.
Conclusion
PMOS is a multifaceted endocrine and metabolic condition in which hormonal, reproductive, and metabolic factors may occur together. Inositol, particularly Myo-Inositol and D-Chiro Inositol, has been extensively studied in PMOS, with evidence suggesting potential benefits for selected metabolic and reproductive outcomes. However, current evidence does not establish one particular inositol formulation, ratio, or dosage as universally preferred.
Nutritional approaches may therefore be considered as part of an individualized approach to PMOS management, alongside appropriate medical care, lifestyle measures, and regular clinical assessment.
References
- Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329–2339. doi:10.1016/S0140-6736(26)00717-8
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad762
- Fitz V, Graca S, Mahalingaiah S, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630–1655. doi:10.1210/clinem/dgad762